SYNCROSOME
Private Company
Funding information not available
Overview
Syncrosome operates as a specialized preclinical CRO, offering high-content efficacy data through a suite of validated in vivo disease models to support pharmaceutical R&D. Its core services include detailed pharmacological characterization, from functional and physiological assessments to cellular and molecular biomarker analysis. The recent acquisition by the larger ETAP-Lab Group provides it with enhanced stability and potential for service expansion within a well-established CRO network. With a reported base of 130 customers, Syncrosome is positioned as a niche player providing critical data for early-stage therapeutic development.
Technology Platform
A portfolio of over 15 validated in vivo disease models across five therapeutic areas, supported by specialized techniques including stereotaxic surgery for intracerebral administration, nose-to-brain delivery studies, and multi-layered biomarker analysis (physiological, functional, cellular, molecular, inflammatory).
Opportunities
Risk Factors
Competitive Landscape
Syncrosome competes in the fragmented preclinical CRO market, differentiating itself as a specialist in high-content, validated in vivo disease models, particularly for CNS and complex cardiovascular conditions. It faces competition from large global CROs (e.g., Charles River, Labcorp) with broad capabilities and smaller niche specialists. Its acquisition by ETAP-Lab Group strengthens its position against standalone competitors.